Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.69 | 4.92 | 5.53 | 6.77 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.02 | 3.23 | 3.62 | 5.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.14 | 1.00 | 0.96 | 0.69 | |
Capex/Depreciation |
0.00 | 0.00 | (1.75) | (1.75) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.08) | (1.11) | (1.22) | (0.70) | |
Cash per Share |
2.94 | 3.69 | 4.81 | 6.03 | |
Shareholders Equity per Share |
3.01 | 3.54 | 4.57 | 5.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.01 | 3.54 | 4.57 | 5.78 | |
Free Cash Flow |
(9.64) | (9.58) | (10.55) | (6.01) | |
Working Capital |
25.56 | 29.21 | 37.36 | 47.45 | |
Capital Expenditures |
— | — | (0.01) | (0.01) | |
Net Current Asset Value |
25.56 | 29.21 | 37.36 | 47.45 | |
| Other line items | |||||
Quick Ratio |
4.81 | 4.27 | 5.02 | 6.32 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.08) | (1.11) | (1.22) | (0.70) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.99 | 1.87 | 2.49 | 2.55 | |
Average Inventory |
1.55 | — | 1.55 | — | |
Average Assets |
48.40 | 54.35 | 62.03 | 68.74 | |
Average Common Equity |
42.26 | 47.90 | 55.42 | 61.73 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026